Tag: monoclonal antibody
-
Befrena: Elanco’s Anti-IL31 Therapy for Canine Dermatitis
Overview of Befrena’s U.S. Regulatory Milestone Elanco announced that Befrena™ (tirnovetmab), a novel anti-IL31 monoclonal antibody injection, has received approval from the U.S. Department of Agriculture (USDA). This marks a significant regulatory achievement for Elanco in the estimated $1.3 billion U.S. canine dermatology market, and it introduces a new targeted option for dogs suffering from…
-
Elanco Wins USDA Nod for Befrena (tirnovetmab): A New Targeted Therapy for Canine Atopic Dermatitis
Overview: A New Anti-IL31 Monoclonal Antibody for Dogs Elanco announced USDA approval for Befrena™ (tirnovetmab), a novel anti-IL31 monoclonal antibody injection designed to help dogs manage allergic and atopic dermatitis. As the canine dermatology market grows—estimated at about $1.3 billion in the United States—Befrena represents the company’s second dermatology product approval in under 18 months,…
-
Monoclonal Antibody Protects Children from RSV: Real-World Evidence
Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…
-
Monoclonal Antibody nirsevimab Beyfortus Shields Children from RSV
New Evidence Supports nirsevimab Beyfortus in RSV Prevention A comprehensive real-world study published in the Journal of Infection highlights the protective role of the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, against respiratory syncytial virus (RSV) in children. The findings add to the growing body of evidence that this preventive treatment can reduce RSV infections…
-
Monoclonal Antibody Protects Children from RSV: Real-World Insights
RSV’s Burden on Young Lungs Respiratory syncytial virus (RSV) remains a leading cause of hospitalization for infants and young children worldwide. While most kids recover with supportive care, a subset experiences severe disease that can require intensive care. In this context, scientists have been pursuing preventive strategies beyond vaccines, including long-acting monoclonal antibodies that offer…